{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-06-20",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 3
    }
  },
  "results": [
    {
      "discontinued_date": "06/04/2026",
      "update_type": "New",
      "initial_posting_date": "06/04/2026",
      "package_ndc": "0169-4303-30",
      "generic_name": "Semaglutide Tablet",
      "contact_info": "833-493-4689",
      "related_info": "Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.",
      "openfda": {
        "application_number": [
          "NDA213051"
        ],
        "brand_name": [
          "RYBELSUS"
        ],
        "generic_name": [
          "ORAL SEMAGLUTIDE"
        ],
        "manufacturer_name": [
          "Novo Nordisk Pharmaceutical Industries, LP"
        ],
        "product_ndc": [
          "0169-4303",
          "0169-1715",
          "0169-1704",
          "0169-1709",
          "0169-4307",
          "0169-4314",
          "0169-4815",
          "0169-4804",
          "0169-4809"
        ],
        "product_type": [
          "HUMAN PRESCRIPTION DRUG"
        ],
        "route": [
          "ORAL"
        ],
        "substance_name": [
          "SEMAGLUTIDE"
        ],
        "rxcui": [
          "2200644",
          "2200650",
          "2200652",
          "2200654",
          "2200656",
          "2200658",
          "2707547",
          "2707549",
          "2707551",
          "2707553",
          "2707555",
          "2707557",
          "2736944",
          "2736946",
          "2736948"
        ],
        "spl_id": [
          "5176eed4-f8f8-4f88-a079-11f16864f40a"
        ],
        "spl_set_id": [
          "27f15fac-7d98-4114-a2ec-92494a91da98"
        ],
        "package_ndc": [
          "0169-1715-30",
          "0169-1715-90",
          "0169-1704-30",
          "0169-1709-30",
          "0169-4303-01",
          "0169-4303-13",
          "0169-4303-90",
          "0169-4303-93",
          "0169-4303-30",
          "0169-4303-99",
          "0169-4307-01",
          "0169-4307-13",
          "0169-4307-30",
          "0169-4314-01",
          "0169-4314-13",
          "0169-4314-30",
          "0169-4815-30",
          "0169-4815-90",
          "0169-4804-30",
          "0169-4809-30"
        ],
        "nui": [
          "N0000178480",
          "M0160181",
          "N0000020058"
        ],
        "pharm_class_epc": [
          "GLP-1 Receptor Agonist [EPC]"
        ],
        "pharm_class_cs": [
          "Glucagon-Like Peptide 1 [CS]"
        ],
        "pharm_class_moa": [
          "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]"
        ],
        "unii": [
          "53AXN4NNHX"
        ]
      },
      "update_date": "06/04/2026",
      "therapeutic_category": [
        "Endocrinology/Metabolism"
      ],
      "dosage_form": "Tablet",
      "presentation": "Rybelsus, Tablet, 3 mg (NDC 0169-4303-30)",
      "company_name": "Novo Nordisk, Inc.",
      "status": "To Be Discontinued"
    }
  ]
}